- Home
- DQ vs INVA Comparison
DQ vs INVA Comparison
Compare DQ & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- INVA
- Stock Information
- Founded
- DQ 2006
- INVA 1996
- Country
- DQ China
- INVA United States
- Employees
- DQ N/A
- INVA N/A
- Industry
- DQ Semiconductors
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- INVA Health Care
- Exchange
- DQ Nasdaq
- INVA Nasdaq
- Market Cap
- DQ 1.4B
- INVA 1.2B
- IPO Year
- DQ 2010
- INVA 2004
- Fundamental
- Price
- DQ $19.07
- INVA $18.58
- Analyst Decision
- DQ Hold
- INVA Buy
- Analyst Count
- DQ 5
- INVA 1
- Target Price
- DQ $20.31
- INVA N/A
- AVG Volume (30 Days)
- DQ 798.7K
- INVA 722.9K
- Earning Date
- DQ 02-26-2025
- INVA 02-27-2025
- Dividend Yield
- DQ N/A
- INVA N/A
- EPS Growth
- DQ N/A
- INVA 46.55
- EPS
- DQ N/A
- INVA 0.99
- Revenue
- DQ $1,310,019,000.00
- INVA $352,745,000.00
- Revenue This Year
- DQ N/A
- INVA $16.20
- Revenue Next Year
- DQ $49.41
- INVA N/A
- P/E Ratio
- DQ N/A
- INVA $18.76
- Revenue Growth
- DQ N/A
- INVA 21.46
- 52 Week Low
- DQ $13.62
- INVA $14.33
- 52 Week High
- DQ $30.85
- INVA $21.28
- Technical
- Relative Strength Index (RSI)
- DQ 47.43
- INVA 63.73
- Support Level
- DQ $18.52
- INVA $17.01
- Resistance Level
- DQ $19.78
- INVA $17.53
- Average True Range (ATR)
- DQ 1.00
- INVA 0.28
- MACD
- DQ -0.07
- INVA 0.18
- Stochastic Oscillator
- DQ 19.34
- INVA 98.12
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.